<DOC>
	<DOCNO>NCT00670007</DOCNO>
	<brief_summary>This study continuation placebo-controlled study CE1226_4001 ( NCT00261833 ) evaluate efficacy safety Zemaira速 intravenous ( i.v ) . administration subject emphysema due alpha1-proteinase inhibitor deficiency . The long-term verification disease-modifying benefit Zemaira速 progression emphysema assess volume-adjusted lung density , measure yearly compute tomography ( CT ) .</brief_summary>
	<brief_title>Extension Study Zemaira速 i.v . Administration Subjects With Emphysema Due alpha1-proteinase Inhibitor Deficiency .</brief_title>
	<detailed_description />
	<mesh_term>Emphysema</mesh_term>
	<mesh_term>Pulmonary Emphysema</mesh_term>
	<mesh_term>Alpha 1-Antitrypsin Deficiency</mesh_term>
	<mesh_term>Alpha 1-Antitrypsin</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<criteria>Subjects complete 2year treatment observation period Phase 3/4 Zemaira速 CE1226_4001 study ( NCT00261833 ) willing sign inform consent Males , nonpregnant , nonlactating female , whose screening pregnancy test negative use contraceptive method deem reliable investigator Individuals reside US Current evidence alcohol abuse abuse drug barbiturate , benzodiazepine , amphetamine , cocaine , opioids , cannabinoids History allergy , anaphylactic reaction , severe systemic response human plasma derive product , know mannitol hypersensitivity , history prior adverse reaction mannitol Current tobacco smoker ( smoke must discontinue least 6 month prior study participation ) Conditions behavior interfere attend schedule study visit opinion investigator History noncompliance Administration experimental new drug participation investigation market product Inability perform necessary study procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Alpha1-proteinase inhibitor deficiency</keyword>
	<keyword>Chronic augmentation maintenance therapy</keyword>
	<keyword>Emphysema</keyword>
	<keyword>Emphysema due Alpha 1-proteinase inhibitor deficiency</keyword>
</DOC>